Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Louisville
With
James Graham Brown Cancer Center
Sanofi
The purpose of this study is to determine the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of Oxaliplatin in combination with Capecitabine and radiation in subjects with non-small cell lung cancer.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
histologically proven non-small cell lung cancer
inoperable Stage III A or B NSCLC
must have measurable disease by RECIST criteria
no more than one prior chemotherapy for advanced disease
ECOG Performance Status of 0, 1, or 2
must be able to swallow pills or have a working gastric feeding tube and no evidence of malabsorption
negative serum beta-HCG test and under active contraception (for females of childbearing potential)
no known allergies to any of the study drugs
willingness to sign an informed consent
You may not be if
women who are pregnant or breastfeeding
ANC of less than 1500/mm3
platelet count of less than 100,000/mm3
estimated creatinine clearance of less than 50 cc/min (as measured by the Cockcroft-Gault equation)
bilirubin of less than 2mg/dl
SGPT of greater than 2x nl
peripheral neuropathy of Grade 2 or higher
more than one previous chemotherapy and previous radiation therapy to the chest
a history of CHF/MI or other significant cardiac history within the last six months
